Platelet-activating factor acetylhydrolase and transacetylase activities in human aorta and mammary artery

Journal of Lipid Research

Volumn 49, Issue 10, 2008, Pages 2240-2249

  Tsoukatos, Demokritos C ^a   Brochériou, Isabelle ^b,c   Moussis, Vassilios ^a   Panopoulou, Christina P ^a   Christofidou, Elena D ^a   Koussissis, Stamatis ^d   Sismanidis, Socratis ^e   Ninio, Ewa ^c   Siminelakis, Stavros ^e  

^a UNIVERSITY OF IOANNINA   (Greece)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITY OF WEST ATTICA   (Greece)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Atherogenesis; Atherosclerosis; Lipoproteins; Macrophages; Oxidized LDL; Smooth muscle cells

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 1 O ALKYLGLYCERO 3 PHOSPHORYLCHOLINE; ACYLTRANSFERASE; THROMBOCYTE ACTIVATING FACTOR;

ADULT; AORTA; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MAMMARY ARTERY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLTRANSFERASES; ANIMALS; AORTA; ATHEROSCLEROSIS; CATTLE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAMMARY ARTERIES; MIDDLE AGED; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 64749085060     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800188-JLR200     Document Type: Article

References (50)

1. Prescott, S. M., G. A. Zimmerman, D. M. Stafforini, and T. M. McIntyre. 2000. Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 69: 419-445.
2. Montrucchio, G., G. Alloatti, and G. Camussi. 2000. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol. Rev. 80: 1669-1699.
3. Honda, Z., M. Nakamura, I. Miki, M. Minami, T. Watanabe, Y. Seyama, H. Okado, H. Toh, K. Ito, T. Miyamoto, et al. 1991. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature. 349: 342-346.
4. Izumi, T., and T. Shimizu. 1995. Platelet-activating factor receptor: gene expression and signal transduction. Biochim. Biophys. Acta. 1259: 317-333.
5. Tanaka, T., M. Iimori, H. Tsukatani, and A. Tokumura. 1994. Platelet-aggregating effects of platelet-activating factor-like phospholipids formed by oxidation of phosphatidylcholines containing an sn-2-polyunsaturated fatty acyl group. Biochim. Biophys. Acta. 1210: 202-208.
6. Androulakis, N., H. Durand, E. Ninio, and D. C. Tsoukatos. 2005. Molecular and mechanistic characterization of platelet-activating factor-like bioactivity produced upon LDL oxidation. J. Lipid Res. 46: 1923-1932.
7. Ross, R. 1999. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340: 115-126.
8. Ninio, E. 2005. Phospholipid mediators in the wall: involvement in atherosclerosis. Curr. Opin. Clin. Nutr. Metab. Care. 8: 123-131.
9. Snyder, F. 1995. Platelet-activating factor: the biosynthetic and catabolic enzymes. Biochem. J. 305: 689-705.
10. Karabina, S. A., and E. Ninio. 2006. Plasma PAF-acetylhydrolase: an unfulfilled promise? Biochim. Biophys. Acta. 1761: 1351-1358.
11. Berliner, J. A., G. Subbanagounder, N. Leitinger, A. D. Watson, and D. Vora. 2001. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc. Med. 11: 142-147.
12. Smiley, P. L., K. E. Stremler, S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 1991. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J. Biol. Chem. 266: 11104-11110.
13. Chakraborti, S. 2003. Phospholipase A2 isoforms: a perspective. Cell. Signal. 15: 637-665.
14. Farr, R. S., C. P. Cox, M. L. Wardlow, and R. Jorgensen. 1980. Preliminary studies of an acid labile factor (ALF) in human sera that inactivates platelet activating factor (PAF). Clin. Immunol. Immunopathol. 15: 318-330.
15. Blank, M. L., T. Lee, V. Fitzgerald, and F. Snyder. 1981. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J. Biol. Chem. 256: 175-178.
16. Stafforini, D. M., S. M. Prescott, and T. M. McIntyre. 1987. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J. Biol. Chem. 262: 4223-4230.
17. Stremler, K. E., D. M. Stafforini, S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 1989. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J. Biol. Chem. 264: 5331-5334.
18. Falk, E., P. K. Shah, and V. Fuster. 1995. Coronary plaque disruption. Circulation. 92: 657-671.
19. Liapikos, T. A., S. Antonopoulou, S-A. P. Karabina, D. C. Tsoukatos, C. A. Demopoulos, and A. D. Tselepis. 1994. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim. Biophys. Acta. 1212: 353-360.
20. Tokumura, A., M. Toujima, Y. Yoshioka, and K. Fukuzawa. 1996. Lipid peroxidation in low density lipoproteins from human plasma and egg yolk promotes accumulation of 1-acyl analogues of platelet-activating factor-like lipid. Lipids. 31: 1251-1258.
21. Tsoukatos, D. C., M. Arborati, T. Liapikos, K. L. Clay, R. C. Murphy, M. J. Chapman, and E. Ninio. 1997. Copper-catalyzed oxidation mediates PAF formation in human LDL subspecies. Protective role of PAF:acetylhydrolase in dense LDL. Arterioscler Thromb. Vasc. Biol. 17: 3505-3512.
22. Lehr, H. A., J. Seemuller, C. Hubner, M. D. Menger, and K. Messmer. 1993. Oxidized LDL-induced leukocyte/endothelium, interaction in vivo involves the receptor for platelet-activating factor. Arterioscler. Thromb. 13: 1013-1018.
23. Tjoelker, L. W., C. Wilder, C. Eberhardt, D. M. Stafforini, G. Dietsch, B. Schimpf, S. Hooper, H. Le Trong, L. S. Cousens, G. A. Zimmerman, et al. 1995. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 374: 549-553.
24. Quarck, R., B. De Geest, D. Stengel, A. Mertens, M. Lox, G. Theilmeier, C. Michiels, M. Raes, H. Bult, D. Collen, et al. 2001. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation. 103: 2495-2500.
25. Vadas, P., M. Gold, B. Perelman, G. M. Liss, G. Lack, T. Blyth, F. E. Simons, K. J. Simons, D. Cass, and J. Yeung. 2008. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N. Engl. J. Med. 358: 79-81.
26. Liu, M., and P. V. Subbaiah. 1994. Hydrolysis and transesterification of platelet-activating factor by lecithin-cholesterol acyltransferase. Proc. Natl. Acad. Sci. USA. 91: 6035-6039.
27. Tsoukatos, D. C., T. A. Liapikos, A. D. Tselepis, M. J. Chapman, and E. Ninio. 2001. Platelet-activating factor acetylhydrolase and trans-acetylase activities in human plasma low-density lipoprotein. Biochem. J, 357: 457-464.
28. Cox, J. L., D. A. Chiasson, and A. I. Gotlieb. 1991. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog. Cardiovasc. Dis. 34: 45-68.
29. Mills, N. L., and C. Swayze Rigby. 1991. Techniques of coronary artery operations and reoperations. In Glenn's Thoracic and Cardiovascular Surgery. A. E. Bauer, A. S. Geha, G. L. Hammond, H. Laks, and K. S. Naunheim, editors. Churchill Livingston, Philadelphia. 1771-1789.
30. Bligh, E. G., and W.J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
31. Tselepis, A. D., C. Dentan, S. A. P. Karabiria, M. J. Chapman, and E. Ninio. 1995. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler. Thromb. Vasc. Biol. 15: 1764-1773.
32. Bossant, M. J., E. Ninio, D. Delautier, and J. Benveniste. 1990. Bio-assay of paf-acether by rabbit platelet aggregation. In Methods in Enzymology. R. C. Murphy and F. A. Fitzpatrick, editors. Academic Press, San Diego. 125-130.
33. Benveniste, J., J-P. Le Couedic, J. Polonsky, and M. Tence. 1977. Structural analysis of purified platelet-activating factor by lipases. Nature. 269: 170-171.
34. Lekka, M. E., D. C. Tsoukatos, A. D. Tselepis, and V. M. Kapoulas. 1988. Semisynthetic preparation of 1-O-hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor). Z. Naturforsch. 43: 665-670.
35. Hakkinen, T., J. S. Luoma, M. O. Hiltunen, C. H. Macphee, K. J. Milliner, L. Patel, S. Q. Rice, D. G. Tew, K. Karkola, and S. Yla-Herttuala. 1999. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 19: 2909-2917.
36. Brocheìriou, I., D. Stengel, L. Mattsson-Hultein, J. Stankova, M. Rola-Pleszczynski, F. Koskas, O. Wiklund, Y. Le Charpentier, and E. Ninio. 2000. Expression of platelet-activating factor receptor in human carotid atherosclerotic plaques: relevance to progression of atherosclerosis. Cirrulation. 102: 2569-2575.
37. Stengel, D., C. O'Neil, I. Brochériou, S. A. Karabina, H. Durand, N. M. Caplice, J. G. Pickering, and E. Ninio. 2006. PAF-receptor is preferentially expressed in a distinct synthetic phenotype of smooth muscle cells cloned from human internal thoracic artery: functional implications in cell migration. Biochem. Biophys. Res. Commun. 346: 693-699.
38. Mueller, H. W, C. A. Haught, J. M. McNatt, K. Cui, S. J. Gaskell, D. A. Johnston, and J. T. Willerson. 1995. Measurement of platelet-activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. Circ. Res. 77: 54-63.
39. Lupia, E., A. Pucci, P. Peasso, M. Merlo, P. Baron, C. Zanini, L. Del Sorbo, S. Rizea-Savu, L. Silvestro, M. Forni, et al. 2003. Intra-plaque production of platelet-activating factor correlates with neoangio-genesis in human carotid atherosclerotic lesions. Int. J. Mol. Med. 12: 327-334.
40. Marathe, G. K., S. S. Davies, K. A. Harrison, A. R. Silva, R. C. Murphy, H. Castro-Faria-Neto, S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 1999. Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J. Biol. Chem. 274: 28395-28404.
41. Quinn, M. T., S. Parthasarathy, L. G. Fong, and D. Steinberg. 1987. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA. 84: 2995-2998.
42. 2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler. Thromb. Vasc. Biol. 17: 2257-2263.
43. 2 in atherosclerosis. Atherosclerosis. 132: 1-8.
44. 2 on human endothelial cell function. FASEB J. 20: 2547-2549.
45. Witztum, J. L., and D. Steinberg. 1991. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88: 1785-1792.
46. 2 activity in endothelial cell-induced modification of low density lipoprotein. Proc. Natl. Acad. Sci. USA. 82: 3000-3004.
47. Harayama, T., H. Shindou, R. Ogasavara, A. Suwabe, and T. Shimizu. 2008. Identification of a novel non-inflammatory biosynthetic pathway of platelet-activating factor. J. Biol. Chem. 283: 11097-11106.
48. Yl-̈Herttuala, S., W. Palinski, M. E. Rosenfeld, S. Parthasarathy, T. E. Carew, S. Butler, J. L. Witztum, and D. Steinberg. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84: 1086-1095.
49. Palmantier, R., A. Dulioust, H. Maiza, J. Benveniste, and E. Ninio. 1989. Biosynthesis of paf-acether. XIV. Paf-acether output in murine peritoneal macrophages is regulated by the level of acetylhydrolase. Biochem. Biophys. Res. Commun. 162: 475-482.
50. Elstad, M. R., D. M. Stafforini, T. M. McIntyre, S. M. Prescott, and G. A. Zimmerman. 1989. Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor. J. Biol. Chem. 264: 8467-8470.